United Therapeutics announces FDA acceptance of Trevyent new drug application for review

United Therapeutics

11 September 2019 - United Therapeutics today announced that the U.S. FDA has accepted for review the new drug application for Trevyent (treprostinil) for the treatment of pulmonary arterial hypertension. 

The FDA assigned the application a Prescription Drug User Fee Act target action date of 27 April 2020. 

Trevyent is a post-phase III development-stage drug-device combination product that combines two-day, single use, disposable PatchPump technology with treprostinil, for the subcutaneous treatment of pulmonary arterial hypertension.

Read United Therapeutics press release

Michael Wonder

Posted by:

Michael Wonder

Posted in:

Medicine , US , Dossier